Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
2018-08-22

Ark Biosciences (Ark) to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018


Ark has submitted an abstract reporting single dose clinical efficacy of its novel RSV F-protein inhibitor Ziresovir, formerly known as AK0529, in infants hospitalized for lower respiratory tract infection with naturally acquired RSV infection. The data to be presented is from the Phase II ‘VICTOR (Viral Inhibition in Children for Treatment of RSV)’ study, “A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection”.